Third-line treatment of HER2-positive advanced breast cancer: From no standard to a Pandora's box
- 1 January 2021
- journal article
- review article
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
- Vol. 1875 (1) , 188487
Abstract
No abstract availableKeywords
Funding Information
- Ministero della Salute
This publication has 59 references indexed in Scilit:
- Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast CancerNew England Journal of Medicine, 2012
- Central Nervous System Metastases in Patients with HER2-Positive Metastatic Breast Cancer: Incidence, Treatment, and Survival in Patients from registHERClinical Cancer Research, 2011
- Trastuzumab beyond progression in HER2-positive advanced breast cancer: The Royal Marsden experienceBritish Journal of Cancer, 2011
- Continued Use of Trastuzumab Beyond Disease Progression in the National Comprehensive Cancer Network: Should We Practice Ahead of the Evidence?The Oncologist, 2011
- Randomized Study of Lapatinib Alone or in Combination With Trastuzumab in Women With ErbB2-Positive, Trastuzumab-Refractory Metastatic Breast CancerJournal of Clinical Oncology, 2010
- Trastuzumab Beyond Progression in Human Epidermal Growth Factor Receptor 2–Positive Advanced Breast Cancer: A German Breast Group 26/Breast International Group 03-05 StudyJournal of Clinical Oncology, 2009
- Trastuzumab Combined with Pegylated Liposomal Doxorubicin in Patients with Metastatic Breast CancerOncology, 2009
- A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analysesBreast Cancer Research and Treatment, 2008
- The role of platinum-based therapy for HER-2-positive breast cancerBreast Cancer Online, 2006
- Breast Cancer–Associated PIK3CA Mutations Are Oncogenic in Mammary Epithelial CellsCancer Research, 2005